Characterization of peripheral nerve sheath tumors with 3T proton MR spectroscopy.

Abstract

BACKGROUND AND PURPOSE:

The characterization of peripheral nerve sheath tumors is challenging. The purpose here was to investigate the diagnostic value of quantitative proton MR spectroscopy at 3T for the characterization of peripheral nerve sheath tumors as benign or malignant, compared with PET.

MATERIALS AND METHODS:

Twenty participants with 24 peripheral nerve sheath tumors underwent MR spectroscopy by use of a point-resolved sequence (TE, 135 ms). Six voxels were placed in 4 histologically proven malignant peripheral nerve sheath tumors and 22 voxels in 20 benign peripheral nerve sheath tumors (9 histologically proven, 11 with documented stability). The presence or absence of a trimethylamine signal was evaluated, the trimethylamine concentration estimated by use of phantom replacement methodology, and the trimethylamine fraction relative to Cr measured. MR spectroscopy results for benign and malignant peripheral nerve sheath tumors were compared by use of a Mann-Whitney test, and concordance or discordance with PET findings was recorded.

RESULTS:

In all malignant tumors and in 9 of 18 benign peripheral nerve sheath tumors, a trimethylamine peak was detected, offering the presence of trimethylamine as a sensitive (100%), but not specific (50%), marker of malignant disease. Trimethylamine concentrations (2.2 ± 2.8 vs 6.6 ± 5.8 institutional units; P < .049) and the trimethylamine fraction (27 ± 42 vs 88 ± 22%; P < .012) were lower in benign than malignant peripheral nerve sheath tumors. A trimethylamine fraction threshold of 50% resulted in 100% sensitivity (95% CI, 58.0%-100%) and 72.2% (95% CI, 59.5%-75%) specificity for distinguishing benign from malignant disease. MR spectroscopy and PET results were concordant in 12 of 16 cases, (2 false-positive results for MR spectroscopy and PET each).

CONCLUSIONS:

Quantitative measurement of trimethylamine concentration by use of MR spectroscopy is feasible in peripheral nerve sheath tumors and shows promise as a method for the differentiation of benign and malignant lesions. Trimethylamine presence within a peripheral nerve sheath tumor is a sensitive marker of malignant disease, but quantitative measurement of trimethylamine content is required to improve specificity.

• Authors: L M Fayad, X Wang, J O Blakeley, D J Durand, M A Jacobs, S Demehri, T K Subhawong, T Soldatos, P B Barker
• Journal: AJNR. American journal of neuroradiology (AJNR Am J Neuroradiol) Vol. 35 Issue 5 Pg. 1035-41 (May 2014) ISSN: 1936-959X [Electronic] United States
• PMID: 24287094 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 by American Journal of Neuroradiology.

Chemical References

• Biomarkers, Tumor
• Methylamines
• trimethylamine

Topics

• Adolescent
• Adult
• Aged
• Algorithms
• Biomarkers, Tumor (analysis)
• Child
• Diagnosis, Computer-Assisted (methods)
• Female
• Humans
• Male
• Methylamines (analysis)
• Middle Aged
• Nerve Sheath Neoplasms (chemistry, diagnosis)
• Proton Magnetic Resonance Spectroscopy (methods)
• Reproducibility of Results
• Sensitivity and Specificity
• Young Adult